Status and phase
Conditions
Treatments
About
This investigator-initiated trial aims to evaluate the safety and efficacy of CHT101 in patients with relapsed refractory systemic lupus erythematosus.
Full description
This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of CHT101 in patients with relapsed refractory systemic lupus erythematosus.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
15 participants in 1 patient group
Loading...
Central trial contact
Xiaojun Tang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal